Meltem Cetin

Meltem Cetin

Auto-generated profile, based on publicly available information

Meltem Cetin

Atatürk Universitesi

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2010 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
MCMeltem Cetin
Meltem Cetin
AAAlptug Atila
Alptug Atila
YKYucel Kadioglu
Yucel Kadioglu

24 August 2011 in Pharmaceutical Development and Technology
Verified
Journal Article
Closed access
MCMeltem Cetin
Meltem Cetin
AAAlptug Atila
Alptug Atila
SSSelma Sahin
Selma Sahin
IVImran Vural
Imran Vural
The aim of the present study was to develop and characterize metformin HCl-loaded nanoparticle formulations. Nanoparticles were prepared by the nanoprecipitation method using both a single polymer (Eudragit®RSPO) and a polymer mixture (Eudragit/PLGA). The mean particle size ranged from 268.8 to 288 nm and the nanoparticle surface was positively charged (9.72 to 10.1 mV). The highest encapsulation efficiency was observed when Eudragit®RSPO was used. All formulations showed highly reproducible drug release profiles and the in vitro drug release in phosphate buffer (pH = 6.8) ranged from 92 to 100% in 12 h. These results suggest that Eudragit®RSPO or Eudragit/PLGA nanoparticles might represent a promising sustained-release oral formulation for metformin HCl, reducing the necessity of repeated administrations of high doses to maintain effective plasma concentrations, and thus, increasing patient compliance and reducing the incidence of side-effects.

27 May 2020 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
BKBusra Kandilli
Busra Kandilli
AKAfife Busra Ugur Kaplan
Afife Busra Ugur Kaplan
MCMeltem Cetin
Meltem Cetin
NTNuman Taspinar
Numan Taspinar
MEMuhammed Sait Ertugrul
Muhammed Sait Ertugrul
AHAhmet Hacimuftuoglu
Ahmet Hacimuftuoglu
Objective: The aim of this study was to develop the PLGA nanoparticles (NPs) containing carbamazepine (CBZ) and levetiracetam (LEV) combination (CBZ + LEV) for the treatment of epilepsy and to in vitro characterize the prepared NPs. Significance: LEV and CBZ, which are antiepileptic drugs, use in the treatment of epilepsy. Nano-sized formulations are prepared to use for different purposes such as to improve the solubility/the physicochemical properties and bioavailability of drugs, to decrease their doses and frequency of administration, and to reduce side effects of drugs. Methods: CBZ + LEV-PLGA-NPs were prepared by a modified nanoprecipitation method and in vitro and in vivo characterized. Also, the antiepileptic effect of the NPs was evaluated in vivo in a rat epilepsy model. Results: The mean particle size and zeta potential of CBZ + LEV-PLGA-NPs were 180.62 ± 6.260 nm and -27.08 ± 3.110 mV, respectively. The values of encapsulation efficiency (EE%) of CBZ and LEV were 51.00 ± 5.944% and 2.05 ± 0.367%, respectively. CBZ showed a biphasic release profile with initial burst release followed by a sustained release. 90% of CBZ was released from NPs within 2 days, however, % LEV release from NPs reached about 80% within 30 min. Conclusions: Our results showed that a decrease in seizure scores in the group treated with CBZ + LEV was observed and also, CBZ + LEV and CBZ + LEV-PLGA-NPs had similar antiepileptic activity. The NPs containing CBZ + LEV might be beneficial in the treatment of epilepsy.

1 August 2018 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
TGTugba Gulsun
Tugba Gulsun
YCYagmur Akdag Cayli
Yagmur Akdag Cayli
NINihan Izat
Nihan Izat
MCMeltem Cetin
Meltem Cetin
LOLevent Oner
Levent Oner
SSSelma Sahin
Selma Sahin

2 November 2011 in Journal of Microencapsulation
Verified
Journal Article
Closed access
MCMeltem Cetin
Meltem Cetin
MAMustafa Sinan Aktas
Mustafa Sinan Aktas
IVImran Vural
Imran Vural
MOMurat Ozturk
Murat Ozturk
The main objective of this study was to prepare salmon calcitonin (sCT)-loaded Eudragit®RSPO, Eudragit®L100 and Eudragit®-poly(lactic-co-glycolic acid) blend nanoparticles for in vitro and in vivo evaluation as an oral drug delivery system. The prepared nanoparticles ranged in size from 179.7 to 308.9 nm with a polydispersity index between 0.051 and 2.75, and had surface charges ˜ −11 to +6 mV. Efficient sCT encapsulation and release was observed with all the nanoparticle formulations. The polymer type was an important factor that influenced the release characteristics and the in vivo hypocalcemic effect. Nanoparticle formulations were also prepared with sodium taurodeoxycholate (NaTDC) and characterized. No statistically significant difference was noted between the hypocalcemic effect of any of the nanoparticle formulations with and without NaTDC (p > 0.05). The use of Eudragit®RSPO nanoparticles appears to be a potential approach for the oral delivery of sCT.

26 February 2020 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
GGGulsah Gundogdu
Gulsah Gundogdu
FMFatma Demirkaya Miloglu
Fatma Demirkaya Miloglu
KGKoksal Gundogdu
Koksal Gundogdu
STSeymanur Yilmaz Tasci
Seymanur Yilmaz Tasci
MAMevlut Albayrak
Mevlut Albayrak
MCMeltem Cetin
Meltem Cetin